GDRX — GoodRx Holdings, Inc.

GoodRx Holdings, Inc. Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics:

• Q4 Revenue: $194.8 million
• Full-Year Revenue: $796.9 million, up 1% year-over-year
• Adjusted EBITDA: Q4 at $65 million; Full-Year at $270.5 million, a 4% increase from 2024
• Prescription Transactions Revenue: Declined 6% year-over-year to $544 million, impacted by Rite Aid's bankruptcy and lower volumes from Integrated Savings Program partners.
• Subscription Revenue: Decreased 3% year-over-year to $83.8 million, although early adoption of condition-specific subscriptions, particularly for weight loss, showed promise.
• Pharma Direct Revenue: Increased 41% year-over-year to $151.4 million, highlighting growth in partnerships with pharmaceutical manufacturers.
• Cash Position: Ended the year with $261.8 million in cash and $80 million in unused credit capacity.

2. Strategic Updates and Business Highlights:

• Pharma Manufacturer Solutions: Rebranded as GoodRx Pharma Direct, focusing on direct-to-consumer strategies and partnerships with pharmaceutical manufacturers to enhance prescription access and affordability.
• Subscription Offerings: Launched condition-specific subscriptions targeting areas like weight loss, erectile dysfunction, and hair loss, with initial positive reception.
• Retail Partnerships: Expanded e-commerce ecosystem, tripling retail footprint and increasing order volume by 83% quarter-over-quarter.
• Employer Direct Program: Introduced to help employers address gaps in traditional insurance coverage by integrating cash pricing.

3. Forward Guidance and Outlook:

• 2026 Revenue Guidance: Expected to be between $750 million and $780 million, reflecting a strategic shift towards long-term growth initiatives.
• Adjusted EBITDA for 2026: Projected to be at least $230 million.
• Pharma Direct Revenue Growth: Anticipated to grow at least 30% year-over-year in 2026.
• Subscription Growth: Expected to see significant contributions from condition-specific subscriptions, particularly in weight loss.

4. Challenges and Points of Concern:

• Declining Prescription Transactions Revenue: Anticipated continued pressure on prescription transactions revenue in 2026 due to the impacts of prior partnerships and market dynamics.
• Monthly Active Consumers: Fell 14% in 2025, though expected to stabilize in 2026.
• Unit Economics Pressure: Lower fees negotiated with partners could impact profitability, with a focus on long-term stability over short-term gains.
• Competitive Pressures: Increased competition in the weight loss market and potential impacts from new entrants and pricing strategies.

5. Notable Q&A Insights:

• Revenue Guidance Clarification: Management indicated that the decline in prescription transaction revenue is due to the loss of significant revenue from Rite Aid and a shift in claims to Pharma Direct.
• Pharma Budget Trends: There is a noted trend of pharmaceutical manufacturers pulling forward budget allocations, which could positively impact GoodRx's partnerships.
• Consumer Engagement: The company emphasized the importance of engaging consumers directly to drive usage across its platform, particularly in light of the competitive landscape.
• Marketing Strategy: GoodRx is focusing on data-driven marketing strategies to optimize spending and support new subscription offerings, particularly in weight loss.

Overall, GoodRx Holdings, Inc. is navigating a transitional phase with a focus on enhancing its Pharma Direct offerings and subscription services, while addressing challenges in its core prescription transaction revenue. The company remains optimistic about long-term growth despite near-term pressures.